Aktieanalys

Optomed Q4 2022: In line with our expectations - Redeye

Redeye Publicerad: 20 Feb 2023 08:14

Redeye provides an update in relation to Optomed’s Q4 2022 report. We argue the year has been in line with our expectations, with total sales of EUR14.7m (EUR14.9m), which can be compared to our sales estimate of EUR14.5m. We are positive the sales were at the same level as in 2021 due to the uncertainties in China, which has clearly affected the company. We have chosen not to make any changes in our estimates for the following years and look forward to the potential US launch during 2023. We reiterate our base case of EUR8.

Länk till analysen i sin helhet: https://www.redeye.se/research/880529/optomed-q4-2022-in-line-with-our-expectations?utm_source=finwire&utm_medium=RSS

Nyheter om Optomed

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!